Get the content you want anytime you want.
The Annual Conference on Retroviruses and Opportunistic Infections (CROI 2020)

Select coverage from The Annual Conference on Retroviruses and Opportunistic Infections (CROI 2020) is included below:

TB Screening Among People Living With HIV in PEPFAR Countries
A poster presented at CROI 2020 examined rates of TB screening among people living with HIV in PEPFAR supported countries.
People Facing HIV Stigma Are Less Likely To Make Their Next Care Visit
Patients facing HIV stigma may encounter difficulties with retention in care.
George Hanna, MD: Islatravir Presentations at CROI 2020
George Hanna, MD, vice president and therapeutic head of infectious diseases at Merck Laboratories, discusses data from CROI 2020 on islatravir.
Virus-Delivered Anti-HIV Antibody Shows Promise in NIH Study
An antibody gene delivered by a harmless virus produced anti-HIV antibodies for a sustained period.
Timothy Skalland, PhD: Examining HIV Incidence and Viral Burden at the Community Level in the PopART Trial
Higher HIV incidence is associated with higher viral burden, according to results from the PopART trial presented at CROI 2020. 
Kenneth Mayer, MD: Safety and Tolerability of Once-Daily BIC/FTC/TAF for Postexposure Prophylaxis
A poster on antiviral PEP safety and tolerability was presented at CROI 2020.
Kenneth Mayer, MD: Reasons for Suboptimal PrEP Use Among At-Risk US MSM
A new study examining the reasons for suboptimal PrEP use among MSM was presented at CROI 2020.
Trial Data Released for Investigational HIV-1 Capsid Inhibitor
Data from clinical and preclinical studies on the use of the investigational HIV-1 capsid inhibitor GS-6207 were presented via 3 posters at CROI 2020.
Is there a cure? How long until we find it? And will it work for the majority of people living with HIV?